Comparative Efficacy of Peptides vs. Traditional Anabolics

Two Different Mechanisms

Comparing peptides to traditional anabolics is a bit like comparing a sniper rifle to a shotgun. Both get used in physique building, but they are designed for different jobs and carry different risks. This page focuses on raw mass, and on how well the recovery claims made for growth hormone peptides hold up.

Traditional anabolic-androgenic steroids (AAS) are the shotgun. Think testosterone or trenbolone. They work primarily by directly binding to androgen receptors in muscle cells, forcing muscle protein synthesis into overdrive. The result in trials is rapid gains in size and strength.

Peptides, specifically the growth hormone secretagogues (GHS) we're discussing here like ipamorelin or CJC-1295, are the sniper rifle. They don't introduce a new hormone into your body. Instead, they nudge your own pituitary gland to release more of its own growth hormone (GH) in a natural, pulsatile manner. The effect is smaller, and the side-effect profile is different rather than absent. The 'efficacy' question comes down to what target you're actually trying to hit. For tested athletes, as of October 2026 WADA prohibits ipamorelin and CJC-1295 at all times (S2.2.4), just as it does anabolic steroids.

Muscle Mass: Where Anabolics Clearly Lead

If your only goal is to get as big as possible, as fast as possible, nothing on the peptide menu has matched a classic steroid cycle in any trial we found.

The landmark 1996 study by Bhasin et al. (New England Journal of Medicine) is still the reference point here. They randomly assigned 43 healthy men to placebo or 600 mg of testosterone enanthate a week for 10 weeks, with or without weight training. The group that lifted and took testosterone gained 6.1 kg (over 13 pounds) of fat-free mass. The group that took testosterone and didn't lift still gained about 3 kg (7 pounds) of fat-free mass, plus more arm and thigh muscle than placebo. That dose is several times a replacement dose, given under medical supervision.

On the GH side, the longest trial is of MK-677 (ibutamoren), an oral, non-peptide secretagogue acting on the same receptor as ipamorelin. In 65 healthy adults aged 60-81, 25 mg a day for a year raised fat-free mass by 1.1 kg, against a 0.5 kg loss on placebo, with no change in strength or function. The populations differ, so this isn't a head-to-head test, but the gap is large. We found no muscle-outcome trial for ipamorelin or CJC-1295.

But the AAS result comes at a steep price, which is where the 'monitoring' part of this conversation gets serious. Running a cycle like that reliably shuts down your natural testosterone production (HPTA shutdown). Your cholesterol and lipid values often worsen. Your hematocrit can climb to dangerous levels. Estrogen management becomes a regular task. We have a whole page on monitoring protocols for peptide use, but the protocols for AAS are more complex and critical.

Recovery and Joint Claims for GH-Axis Peptides

Peptides can't compete with AAS for raw mass, so the case made for them rests on recovery. When you use a GHS stack like ipamorelin and Mod GRF (CJC-1295 no DAC), you're triggering a pulse of your body's own growth hormone. This leads to a subsequent rise in insulin-like growth factor 1 (IGF-1); small human studies confirm that much. The downstream claims are weaker. As of October 2026, our peptide database rates ipamorelin's evidence as moderate: limited human data, and a Phase 2 trial that missed its primary endpoint.

• Collagen and joints: While AAS make your muscles stronger, they don't appear to do much for the tendons and ligaments that anchor them. GH and IGF-1, however, appear to stimulate collagen synthesis in human tendon and muscle, according to a 2005 review by Doessing and Kjaer that drew mostly on recombinant GH studies. No one has measured tendon or joint outcomes in people using ipamorelin or CJC-1295. Users often say their joints feel better; whether a secretagogue's modest GH pulses are enough to matter is unknown.
• Sleep quality: The best sleep data come from MK-677. In a small 1997 crossover study of eight young adults, 25 mg at bedtime increased deep (stage IV) sleep by about 50% and REM sleep by more than 20% versus placebo. For ipamorelin the picture is mixed. At FDA's October 2024 compounding advisory meeting, a speaker supporting ipamorelin said clinicians commonly report better sleep in patients, but its Phase 2 trial (IV dosing after abdominal surgery) recorded more insomnia than placebo. Users report both better and disrupted sleep. AAS, especially harsh compounds like trenbolone, are notorious among users for disrupting sleep.
• Lipolysis (fat loss): Growth hormone itself is a fat-burning agent. In secretagogue trials, though, fat loss has mostly not appeared; the MK-677 trial found no change in total or visceral fat. Users commonly report getting leaner, usually alongside diet changes.

Any muscle growth is a slow-burn gain, not a rapid increase, and hard to separate from the water retention both trials and users report.

Efficacy at a Glance

Peptide entries refer to ipamorelin and CJC-1295 unless noted.

What Users Report About Combining Them

For many experienced users, the discussion isn't 'AAS vs. Peptides.' It's 'AAS and Peptides.' No controlled study has tested this, so this section describes user reports only.

Users running a moderate testosterone cycle commonly describe adding a bedtime ipamorelin dose, often with Mod GRF, hoping to counteract poor sleep and joint aches. Forum reports usually describe 100-300 mcg of each before bed; vendor guidance lists 200-300 mcg of ipamorelin two to three times a day, which no trial has tested. Some report better sleep and less joint discomfort, while others notice little beyond water retention and tingling hands. With subjective effects and unregulated products, it's hard to know how much comes from the peptide.

Users also describe a role during PCT (Post-Cycle Therapy) or a cruise. When androgen levels plummet after a cycle, the body tends to lose muscle and store fat, and some users run a GHS hoping to hold onto muscle while natural testosterone recovers. We found no study testing this. GH secretagogues also raised fasting glucose and lowered insulin sensitivity in the MK-677 trial, which adds markers to watch. For how the two compare once monitoring load is counted, see our page on net efficacy after monitoring burden.

What We Still Don't Know

If the goal is to be 20 pounds heavier by Christmas and you're prepared to manage a cascade of serious health markers and side effects, the trial data favor anabolics. The open questions sit on the peptide side:

• Whether ipamorelin or CJC-1295 changes tendon, ligament or joint outcomes in people. No human study has measured it.
• Whether bedtime ipamorelin improves sleep. Clinician and user reports say yes, but the only controlled trial found more insomnia, in a very different setting.
• Whether GHS use around an AAS cycle preserves muscle. Only anecdotes exist.

For peptides, efficacy is the net result after you subtract the cost, and the benefit side of that ledger is still mostly unmeasured. Our overview of long-term effects and the comparison of AAS with GH secretagogues and IGF-1 derivatives cover the risk side in more detail.